These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20180789)

  • 41. Safety, tolerability, pharmacokinetics and pharmacodynamics of dexlansoprazole injection in healthy Chinese subjects.
    Li YQ; Yan ZY; Zhang HW; Sun LN; Jiao HW; Wang MF; Yu LY; Yu L; Yuan ZQ; Meng L; Wang YQ
    Eur J Clin Pharmacol; 2017 May; 73(5):547-554. PubMed ID: 28138748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses.
    Wang H; Ou N; Lang L; Shi R; Hu P; Jiang J
    Xenobiotica; 2016 Dec; 46(12):1133-1141. PubMed ID: 26998954
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of Pharmacodynamics between Tegoprazan and Dexlansoprazole Regarding Nocturnal Acid Breakthrough: A Randomized Crossover Study.
    Han S; Choi HY; Kim YH; Choi S; Kim S; Nam JY; Kim B; Song GS; Lim HS; Bae KS
    Gut Liver; 2023 Jan; 17(1):92-99. PubMed ID: 36317518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative analysis of the effect of PO administered acid suppressants on gastric pH in healthy cats.
    Ryan P; Odunayo A; Price J; Hecht S; Hillsman S; Galyon G; Steiner J; Tolbert MK
    J Vet Intern Med; 2020 Sep; 34(5):1879-1885. PubMed ID: 32885499
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.
    Mermelstein J; Mermelstein AC; Chait MM
    Clin Exp Gastroenterol; 2016; 9():163-72. PubMed ID: 27471402
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium).
    Parekh PJ; Oldfield EC; Johnson DA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1215-22. PubMed ID: 24749891
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects.
    Wang H; Lang L; Ou N; Shi R; Hu H; Hu P; Jiang J
    Clin Drug Investig; 2016 Jun; 36(6):463-70. PubMed ID: 27067231
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics of a Modified-Release Dexamphetamine Sulfate Formulation Following Single and Multiple Dosing in Healthy Adults: Comparative Bioavailability with Immediate-Release Dexamphetamine Sulfate, between Strengths, Assessment of Food and Meal Composition Effects.
    Sandersleben HU; Mayer A; Ruhmann M; Dangel O; Schütz H
    Scand J Child Adolesc Psychiatr Psychol; 2023 Jan; 11(1):132-142. PubMed ID: 38033826
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bioavailability of dexlansoprazole delayed-release capsule granules when administered via nasogastric tube or orally via syringe.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2018; 11():381-389. PubMed ID: 30323643
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease.
    Kukulka M; Nudurupati S; Perez MC
    Clin Exp Gastroenterol; 2014; 7():461-71. PubMed ID: 25525378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dexlansoprazole - a new-generation proton pump inhibitor.
    Skrzydło-Radomańska B; Radwan P
    Prz Gastroenterol; 2015; 10(4):191-6. PubMed ID: 26759624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.
    Goh KL; Choi MG; Hsu PI; Chun HJ; Mahachai V; Kachintorn U; Leelakusolvong S; Kim N; Rani AA; Wong BC; Wu J; Chiu CT; Shetty V; Bocobo JC; Chan MM; Lin JT
    J Neurogastroenterol Motil; 2016 Jul; 22(3):355-66. PubMed ID: 26932927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples.
    Sigaroudi A; Stelzer C; Braun T; Frechen S; Hüttner S; Schröter M; Kinzig M; Fuhr U; Holzgrabe U; Sörgel F
    Pharmacology; 2016; 98(1-2):70-2. PubMed ID: 27104875
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Integrated models of population pharmacokinetics and exposure response to optimize dosage regimen for anaprazole sodium in duodenal ulcer.
    Zhang L; Song L; Cui C; Wang C; Zhang Y; Yao X; Liu D
    Eur J Pharm Sci; 2024 Jul; 198():106781. PubMed ID: 38703917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Gastric
    Sun LN; Cao Y; Li YQ; Fang YQ; Zhang HW; Wang MF; Xie LJ; Chen J; Yang ZC; Bian ML; Li H; Zhang PP; Wei JF; Meng L; Zhang XH; Zhao P; Wang YQ
    Front Pharmacol; 2017; 8():670. PubMed ID: 29018343
    [No Abstract]   [Full Text] [Related]  

  • 56. Understanding the Current Evidence on Proton Pump Inhibitor Use and Bone Health.
    Sugiyama T
    Gastroenterology; 2019 Aug; 157(2):585. PubMed ID: 31102658
    [No Abstract]   [Full Text] [Related]  

  • 57. Reply.
    Nieves JW; Perez MC; Metz DC; Hansen KE
    Gastroenterology; 2019 Aug; 157(2):586. PubMed ID: 31260666
    [No Abstract]   [Full Text] [Related]  

  • 58. Breakfast, Lunch, and Dinner.
    J Pain Palliat Care Pharmacother; 2017 Jun; 31(2):95. PubMed ID: 28644749
    [No Abstract]   [Full Text] [Related]  

  • 59. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
    Wu MS; Tan SC; Xiong T
    Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.